Artificial Intelligence (AI) in Genomics

Artificial Intelligence (AI) in Genomics

Global Artificial Intelligence (AI) in Genomics Market to Reach US$8.7 Billion by 2030

The global market for Artificial Intelligence (AI) in Genomics estimated at US$784.2 Million in the year 2023, is expected to reach US$8.7 Billion by 2030, growing at a CAGR of 41.1% over the analysis period 2023-2030. AI in Genomics Software, one of the segments analyzed in the report, is expected to record a 44.2% CAGR and reach US$4.6 Billion by the end of the analysis period. Growth in the AI in Genomics Services segment is estimated at 40.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$213.8 Million While China is Forecast to Grow at 38.0% CAGR

The Artificial Intelligence (AI) in Genomics market in the U.S. is estimated at US$213.8 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 38.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 37.1% and 34.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 26.4% CAGR.

Global Artificial Intelligence (AI) in Genomics Market - Key Trends and Drivers Summarized

Artificial Intelligence (AI) is revolutionizing genomics, significantly enhancing the accuracy and speed of genome sequencing and genetic analysis. By integrating AI with genomics, researchers and healthcare providers can more quickly decode genetic material, facilitating advancements in personalized medicine where treatment plans are tailored to individual genetic profiles. AI`s capacity to handle vast datasets gleaned from electronic medical records has expanded its applications across healthcare, agriculture, and environmental science, contributing to more targeted disease management and therapy options. For instance, AI algorithms can analyze patient health trajectories and predict outcomes with greater precision than traditional methods, profoundly impacting the development of personalized medical approaches and treatments.

In gene therapy, AI plays a pivotal role by providing tools to design effective interventions by analyzing complex genetic data. This capability is vital in enhancing the understanding and treatment of diseases at the genetic level. RNA sequencing technologies, especially RNA-Seq, benefit from AI by offering more accurate quantifications of gene expressions and their variations, thus providing deeper insights into biological processes and potential disease mechanisms. These advancements are not only accelerating the pace of research but also improving the quality and effectiveness of medical treatments and gene therapies, underscoring the critical role of AI in pushing the boundaries of modern medicine and scientific understanding.

However, the integration of AI into genomics raises significant challenges and ethical considerations, particularly concerning the protection and privacy of genetic data and the moral implications of genetic editing. Ensuring the security of sensitive genetic information and adhering to strict regulatory standards are paramount as AI and genomics become more intertwined. Moreover, ethical debates surrounding the potential for creating designer genes highlight the need for careful consideration of how these technologies are applied. The growth of AI in genomics is also driven by factors such as advancements in AI and machine learning technologies, the exponential increase in genomic data, and the growing emphasis on precision medicine. Additionally, reduced sequencing costs, the demand for drug development, strategic collaborations, and increased public and private investment all contribute to the expansion of AI applications in genomics, promising to further advance the field and expand its impact on various aspects of healthcare and medicine.

Select Competitors (Total 23 Featured) -

• Data4Cure
• Deep Genomics
• Fabric Genomics (formerly Omicia)
• Freenome, Inc.
• Genoox
• IBM Corporation
• Illumina, Inc.
• Microsoft Corporation
• NVIDIA Corporation
• Sophia Genetics

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.